CytomX Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CTMX | PYXS | VRXA | JANX | HURA | ONCO.ST | |
|---|---|---|---|---|---|---|
| Market cap | 512.06M | 198.30M | 134.34M | 1.11B | 109.61M | 746.25M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -5.0 | -1.5 | — | -6.9 | -2.8 | -2.4 |
| Price/book | 1.7 | 9.2 | -0.7 | 1.2 | 6.0 | 27.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −48.22% | −58.06% | −90.96% | −35.29% | −33.80% | −66.03% |
| Today | +7.80% | +1.22% | −4.04% | +2.02% | +3.93% | +0.35% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CTMX news ›Critical Contrast: CytomX Therapeutics (NASDAQ:CTMX) versus ProKidney (NASDAQ:PROK)
Posted by Kim Johansen on Oct 27th, 2026 CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) and ProKidney (NASDAQ:PROK – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the…
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2027 - Fast Track Designation is…
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Has Average Target Price of $11.90
Posted by Sarita Garza on Oct 25th, 2026 Get Our Latest Research Report on CytomX Therapeutics Shares of CytomX Therapeutics stock opened at $2.32 on Thursday. The stock’s 50-day moving average is $2.94 and its 200 day moving average is…
CytomX Therapeutics (NASDAQ:CTMX) and Janux Therapeutics (NASDAQ:JANX) Financial Contrast
Posted by Defense World Staff on Oct 24th, 2026 CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) and Janux Therapeutics (NASDAQ:JANX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We…
CytomX Therapeutics (NASDAQ:CTMX) Reaches New 1-Year Low – Should You Sell?
Posted by Defense World Staff on Oct 16th, 2026 CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) shares reached a new 52-week low on Wednesday. The company traded as low as $2.32 and last traded at $2.33, with a volume of…
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), CytomX Therapeutics (CTMX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pharvaris (PHVS), CytomX Therapeutics (CTMX) and Neurogene (NGNE) with bullish sentiments. In a report released today, Jeff Jones from…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net2
- themarketsdaily.com2
- theglobeandmail.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.